Find policies, billing codes, payers, states, and providers

CPT 0018U: ThyraMIR microRNA Thyroid Cancer Risk Assay

CPT code 0018U identifies ThyraMIR, a Proprietary Laboratory Analyses (PLA) molecular diagnostic that analyzes 10 microRNA sequences from a thyroid fine needle aspirate (FNA) and applies an algorithm using patient data to report a positive or negative result for increased thyroid cancer risk. PLA codes matter nationally because they uniquely identify manufacturer- or laboratory-specific tests, enabling payers and providers to track utilization, coverage, and clinical adoption of proprietary diagnostics.

Key payers included in the national coverage context are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical purpose of the assay, the typical service context, and what to expect in payer coverage discussions. The publication summarizes available benchmarks for utilization and reimbursement where reported, highlights policy and coding considerations relevant to PLA codes, and situates the test within thyroid nodule diagnostic workflows. It also outlines common billing modifiers and administrative items for operational planning.

Data not available in the input for associated taxonomies, specific ICD-10 mappings, related codes, and a detailed payer-by-payer coverage matrix.

Customize your policy alerts

Sign up for cpt 0018U policy alerts

Get alerted when payer policies referencing 0018U are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

CPT code 0018U is a Proprietary Laboratory Analyses (PLA) code that describes ThyraMIR by Interpace Diagnostics. The test performs a gene analysis of 10 microRNA sequences from a thyroid fine needle aspirate (FNA) specimen and combines those laboratory results with patient data through an algorithm to report a positive or negative finding for increased thyroid cancer risk.

Service type: Molecular diagnostic laboratory test with algorithmic interpretation
Typical site of service: Clinical laboratory processing FNA specimens; results used in outpatient endocrine, cytology, or pathology settings

Explore openpayer tools

View all tools

Find policies, billing codes, payers, states, and providers

CPT 0018U: ThyraMIR microRNA Thyroid Cancer Risk Assay

Data not available in the input for associated taxonomies, specific ICD-10 mappings, related codes, and a detailed payer-by-payer coverage matrix.

Customize your policy alerts

Sign up for cpt 0018U policy alerts

Get alerted when payer policies referencing 0018U are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

Service type: Molecular diagnostic laboratory test with algorithmic interpretation
Typical site of service: Clinical laboratory processing FNA specimens; results used in outpatient endocrine, cytology, or pathology settings

Clinical & Coding Specifications

Clinical Context

A typical patient is a 35–70-year-old adult presenting to an endocrinologist or otolaryngologist with a thyroid nodule identified on clinical exam or ultrasound. Ultrasound-guided fine needle aspiration (FNA) is performed and cytology returns an indeterminate result (for example, Bethesda category III: atypia of undetermined significance/follicular lesion of undetermined significance, or Bethesda IV: follicular neoplasm/suspicious for a follicular neoplasm). The treating clinician sends residual FNA material or a dedicated FNA specimen to a reference laboratory for molecular testing using the ThyraMIR assay (0018U).

The laboratory receives the FNA specimen, extracts RNA, measures expression of the panel of 10 microRNA sequences, and combines the molecular results with available clinical data through the proprietary algorithm to generate a report indicating increased or decreased risk of thyroid malignancy. The result is returned to the ordering provider, who integrates it with cytology, ultrasound features, patient risk factors, and patient preferences to inform management (surveillance versus diagnostic/therapeutic surgery). Typical sites of service are outpatient clinics, ambulatory surgery centers for the FNA procedure, and independent or hospital-based clinical reference laboratories for the 0018U assay. Billing is performed by the laboratory using the PLA code 0018U with appropriate specimen source and specimen collection documentation retained in the medical record.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing only the professional interpretation component if the laboratory or pathologist separately bills interpretation from technical processing.
`TC`	Technical component	Use when billing only the technical component (laboratory processing) of the test.
`90`	Reference (outside) laboratory	Use when the service is performed by a laboratory other than the billing entity (report from a reference lab).
`91`	Repeat clinical diagnostic laboratory test (Note: not in provided list)	Data not available in the input.
`52`	Reduced services	Use when the test was partially performed or limited by specimen inadequacy or partial processing.
`53`	Discontinued procedure	Use if specimen collection or specimen processing was aborted and test could not be completed.
`59`	Distinct procedural service (Note: not in provided list)	Data not available in the input.
`76`	Repeat procedure by same physician (Note: not in provided list)	Data not available in the input.
`78`	Return to operating room for a related procedure (applicable if surgical follow-up after result)	Use when a separate surgical procedure is required within the postoperative global period that is directly related.
`80`	Assistant surgeon	Use when an assistant surgeon is documented during the FNA or surgical procedure in the associated workflow.
`62`	Two surgeons	Use when two surgeons work together as primary surgeons for a related operative procedure.
`90`	Reference laboratory	Duplicate entry avoided; handled above.
`11`	Increased procedural services	Use when work is substantially greater than typically required for the FNA or specimen handling.
`22`	Unusual procedural services	Use when the laboratory or clinician documents significantly greater complexity for specimen collection or interpretation.
`52`	Reduced services	Duplicate entry avoided; handled above.

Taxonomy Code	Specialty	Notes
`207RH0000X`	Otolaryngology (ENT)	Common specialty performing thyroid FNA and coordinating testing.
`207K00000X`	Endocrinology	Frequently orders molecular testing for indeterminate thyroid cytology to guide management.
`2080P0800X`	Pathology	Pathologists oversee cytology interpretation and coordinate molecular testing workflows.
`261QM0800X`	Clinical Laboratory & Laboratory Medicine	Laboratories performing `0018U` testing and reporting results.
`207L00000X`	General Surgery	Surgeons managing thyroid nodules and using results to decide on operative intervention.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`E04.1`	Nontoxic single thyroid nodule	Common indication for FNA and subsequent molecular testing with `0018U` when cytology is indeterminate.
`E04.2`	Nontoxic multinodular goiter	Individual nodules may be sampled and molecular testing used for risk stratification.
`E07.9`	Disorder of thyroid, unspecified	Used when a specific thyroid disorder is not yet defined and FNA/molecular testing is pursued.
`C73`	Malignant neoplasm of thyroid gland	Relevant when suspicion for malignancy exists; `0018U` helps estimate malignancy risk in indeterminate cytology.
`R22.1`	Localized swelling, mass and lump, neck	Symptom code tied to detection of thyroid nodules leading to FNA and molecular analysis.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`10021`	Fine needle aspiration without imaging guidance	Performed when FNA is done freehand; specimen source for `0018U`.
`10022`	Fine needle aspiration with imaging guidance	Performed when ultrasound guidance is used for FNA that provides the specimen for molecular testing with `0018U`.
`88312`	Cytopathology, evaluation of fine needle aspirate, including interpretation and report	Cytology interpretation typically reported alongside molecular testing results; helps determine need for `0018U`.
`88342`	Immunohistochemistry or special stains, per specimen	May be performed on FNA material in parallel to molecular studies for diagnostic clarification.
`81599`	Unlisted molecular pathology procedure	Occasionally used historically when a PLA code was not available; `0018U` supersedes unlisted coding for this proprietary assay.

CPT 0001U: PreciseType HEA Multiplex Erythrocyte Antigen Assay

CPT-0002U-POLYPDX-URINE-METABOLOMIC-ASSAY-ADENOMATOUS-POLYP-RISK

CPT 0002U: Urine Metabolomic Polyp Risk Assay (PolypDX™)

CPT-0003U-OVAR-A-NEXT-GENERATION-OVARIAN-CANCER-RISK-ASSAY

CPT 0003U: Overa™ (OVA1 Next Generation) Ovarian Cancer Risk Assay

CPT-0005U-PROSTATE-EXOSOMEDX-INTELLISCORE-GENE-EXPRESSION-URINE-TEST

CPT 0005U: ExosomeDx Prostate (IntelliScore) Urine Gene Expression Risk Test

CPT-0007U-TOXPROTECT-URINE-DRUG-SCREEN-WITH-DNA-AUTHENTICATION

CPT 0007U: ToxProtect Urine Drug Screen with DNA Authentication

CPT-0008U-H-PYLORI-ANTIBIOTIC-RESISTANCE-SEQUENCING-PANEL

CPT 0008U: H. pylori Antibiotic Resistance Panel, Gene Sequence Analysis

CPT-0009U-DEPARRAY-HER2-FISH-TUMOR-CELL-ISOLATION

CPT 0009U: DEPArray HER2 Tumor‑Cell Isolation with FISH Analysis

CPT-0010U-BACTERIAL-TYPING-WHOLE-GENOME-SEQUENCING-MAYO-CLINIC

CPT 0010U: Bacterial Typing by Whole Genome Sequencing, Mayo Clinic

CPT-0011U-CORDANT-CORE-ALGORITHMIC-ORAL-FLUID-DRUG-TEST

CPT 0011U: Cordant CORE™ Oral Fluid Drug Test with Algorithmic Steady‑State Comparison

CPT-0016U-BCR-ABL1-MAJOR-MINOR-FUSION-TRANSCRIPT-TESTING

CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcript Testing

Showing 1–10 of 536

Frequently Asked Questions

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Explore openpayer tools

View all tools

Clinical & Coding Specifications

Clinical Context

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing only the professional interpretation component if the laboratory or pathologist separately bills interpretation from technical processing.
`TC`	Technical component	Use when billing only the technical component (laboratory processing) of the test.
`90`	Reference (outside) laboratory	Use when the service is performed by a laboratory other than the billing entity (report from a reference lab).
`91`	Repeat clinical diagnostic laboratory test (Note: not in provided list)	Data not available in the input.
`52`	Reduced services	Use when the test was partially performed or limited by specimen inadequacy or partial processing.
`53`	Discontinued procedure	Use if specimen collection or specimen processing was aborted and test could not be completed.
`59`	Distinct procedural service (Note: not in provided list)	Data not available in the input.
`76`	Repeat procedure by same physician (Note: not in provided list)	Data not available in the input.
`78`	Return to operating room for a related procedure (applicable if surgical follow-up after result)	Use when a separate surgical procedure is required within the postoperative global period that is directly related.
`80`	Assistant surgeon	Use when an assistant surgeon is documented during the FNA or surgical procedure in the associated workflow.
`62`	Two surgeons	Use when two surgeons work together as primary surgeons for a related operative procedure.
`90`	Reference laboratory	Duplicate entry avoided; handled above.
`11`	Increased procedural services	Use when work is substantially greater than typically required for the FNA or specimen handling.
`22`	Unusual procedural services	Use when the laboratory or clinician documents significantly greater complexity for specimen collection or interpretation.
`52`	Reduced services	Duplicate entry avoided; handled above.

Taxonomy Code	Specialty	Notes
`207RH0000X`	Otolaryngology (ENT)	Common specialty performing thyroid FNA and coordinating testing.
`207K00000X`	Endocrinology	Frequently orders molecular testing for indeterminate thyroid cytology to guide management.
`2080P0800X`	Pathology	Pathologists oversee cytology interpretation and coordinate molecular testing workflows.
`261QM0800X`	Clinical Laboratory & Laboratory Medicine	Laboratories performing `0018U` testing and reporting results.
`207L00000X`	General Surgery	Surgeons managing thyroid nodules and using results to decide on operative intervention.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`E04.1`	Nontoxic single thyroid nodule	Common indication for FNA and subsequent molecular testing with `0018U` when cytology is indeterminate.
`E04.2`	Nontoxic multinodular goiter	Individual nodules may be sampled and molecular testing used for risk stratification.
`E07.9`	Disorder of thyroid, unspecified	Used when a specific thyroid disorder is not yet defined and FNA/molecular testing is pursued.
`C73`	Malignant neoplasm of thyroid gland	Relevant when suspicion for malignancy exists; `0018U` helps estimate malignancy risk in indeterminate cytology.
`R22.1`	Localized swelling, mass and lump, neck	Symptom code tied to detection of thyroid nodules leading to FNA and molecular analysis.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`10021`	Fine needle aspiration without imaging guidance	Performed when FNA is done freehand; specimen source for `0018U`.
`10022`	Fine needle aspiration with imaging guidance	Performed when ultrasound guidance is used for FNA that provides the specimen for molecular testing with `0018U`.
`88312`	Cytopathology, evaluation of fine needle aspirate, including interpretation and report	Cytology interpretation typically reported alongside molecular testing results; helps determine need for `0018U`.
`88342`	Immunohistochemistry or special stains, per specimen	May be performed on FNA material in parallel to molecular studies for diagnostic clarification.
`81599`	Unlisted molecular pathology procedure	Occasionally used historically when a PLA code was not available; `0018U` supersedes unlisted coding for this proprietary assay.

CPT 0001U: PreciseType HEA Multiplex Erythrocyte Antigen Assay

CPT-0002U-POLYPDX-URINE-METABOLOMIC-ASSAY-ADENOMATOUS-POLYP-RISK

CPT 0002U: Urine Metabolomic Polyp Risk Assay (PolypDX™)

CPT-0003U-OVAR-A-NEXT-GENERATION-OVARIAN-CANCER-RISK-ASSAY

CPT 0003U: Overa™ (OVA1 Next Generation) Ovarian Cancer Risk Assay

CPT-0005U-PROSTATE-EXOSOMEDX-INTELLISCORE-GENE-EXPRESSION-URINE-TEST

CPT 0005U: ExosomeDx Prostate (IntelliScore) Urine Gene Expression Risk Test

CPT-0007U-TOXPROTECT-URINE-DRUG-SCREEN-WITH-DNA-AUTHENTICATION

CPT 0007U: ToxProtect Urine Drug Screen with DNA Authentication

CPT-0008U-H-PYLORI-ANTIBIOTIC-RESISTANCE-SEQUENCING-PANEL

CPT 0008U: H. pylori Antibiotic Resistance Panel, Gene Sequence Analysis

CPT-0009U-DEPARRAY-HER2-FISH-TUMOR-CELL-ISOLATION

CPT 0009U: DEPArray HER2 Tumor‑Cell Isolation with FISH Analysis

CPT-0010U-BACTERIAL-TYPING-WHOLE-GENOME-SEQUENCING-MAYO-CLINIC

CPT 0010U: Bacterial Typing by Whole Genome Sequencing, Mayo Clinic

CPT-0011U-CORDANT-CORE-ALGORITHMIC-ORAL-FLUID-DRUG-TEST

CPT 0011U: Cordant CORE™ Oral Fluid Drug Test with Algorithmic Steady‑State Comparison

CPT-0016U-BCR-ABL1-MAJOR-MINOR-FUSION-TRANSCRIPT-TESTING

CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcript Testing

Showing 1–10 of 536

Frequently Asked Questions

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

OpenPayer

CPT 0018U: ThyraMIR microRNA Thyroid Cancer Risk Assay

Sign up for cpt 0018U policy alerts

Billing Code Overview

OpenPayer

CPT 0018U: ThyraMIR microRNA Thyroid Cancer Risk Assay

Sign up for cpt 0018U policy alerts

Billing Code Overview

Clinical & Coding Specifications

Clinical Context

Coding Specifications

Related Diagnoses

Related CPT Codes

Related Codes

References

Clinical & Coding Specifications

Clinical Context

Coding Specifications

Related Diagnoses

Related CPT Codes

Related Codes

References

CPT 0018U: ThyraMIR microRNA Thyroid Cancer Risk Assay

Sign up for cpt 0018U policy alerts

Billing Code Overview

CPT 0018U: ThyraMIR microRNA Thyroid Cancer Risk Assay

Sign up for cpt 0018U policy alerts

Billing Code Overview

Clinical & Coding Specifications

Clinical Context

Coding Specifications

Related Diagnoses

Related CPT Codes

Related Codes

What does CPT code 0018U represent?

In what clinical situations is ThyraMIR (0018U) typically used?

Who bills CPT 0018U and which billing modifiers are commonly relevant?

What CPT and ICD-10 codes are commonly associated with testing and clinical indications for 0018U?

Which payers cover 0018U and does the page provide specific coverage or reimbursement rates?

References

Clinical & Coding Specifications

Clinical Context

Coding Specifications

Related Diagnoses

Related CPT Codes

Related Codes

What does CPT code 0018U represent?

In what clinical situations is ThyraMIR (0018U) typically used?

Who bills CPT 0018U and which billing modifiers are commonly relevant?

What CPT and ICD-10 codes are commonly associated with testing and clinical indications for 0018U?

Which payers cover 0018U and does the page provide specific coverage or reimbursement rates?

References